Recursion Pharmaceuticals, Inc. (RXRX)
| Market Cap | 1.81B |
| Revenue (ttm) | 65.18M |
| Net Income (ttm) | -377.75M |
| Shares Out | 286.84M |
| EPS (ttm) | -1.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,389,339 |
| Open | 6.16 |
| Previous Close | 6.03 |
| Day's Range | 6.10 - 6.50 |
| 52-Week Range | 5.60 - 15.74 |
| Beta | 0.84 |
| Analysts | Buy |
| Price Target | 9.25 (+46.36%) |
| Earnings Date | Nov 6, 2024 |
About RXRX
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; R... [Read more]
Financial Performance
In 2023, Recursion Pharmaceuticals's revenue was $44.58 million, an increase of 11.88% compared to the previous year's $39.84 million. Losses were -$328.07 million, 37.0% more than in 2022.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is $9.25, which is an increase of 46.36% from the latest price.
News
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug di...
Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform
Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The r...
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor...
Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245
Recursion Pharmaceuticals, Inc. expects to meet with the FDA to discuss the potential of advancing REC-994 for the treatment of patients with cerebral cavernous malformation. REC-1245 is a CDK12-adjac...
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
Recursion and Exscientia Shareholders Approve the Proposed Combination
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler OpenPhenom is a non-commercial, publicly av...
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia Company plans to host update call on Nov 20, 2024 after the anticipat...
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
SALT LAKE CITY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient...
Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma
Kirk Spano and Bhavneesh Sharma talk biotech, pharma, and contrarian buying opportunities. AI is revolutionizing drug discovery by significantly speeding up the process and increasing the probability ...
Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment
Recursion said it was able to use its AI-enabled drug discovery platform to identify a novel target and move all the way to gaining IND approval in less than 18 months.
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
SALT LAKE CITY, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that the U.S. Foo...
Recursion: Path Forward For REC-994 Remains Despite Mixed Response
Recursion Pharmaceuticals, Inc.'s REC-994 was able to show positive safety/tolerability data for the treatment of Cerebral Cavernous Malformation, along with a trend towards improvement. End-of-phase ...
Recursion's blood vessel disorder drug meets main goal in mid-stage study
Recursion Pharmaceuticals said on Tuesday its experimental drug to treat a condition that causes blood vessel malformation met the main goal of safety and tolerability in a mid-stage study.
Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner
Chris Gibson, Recursion co-founder and CEO, joins 'Squawk Box' to discuss the company's $688 million acquisition of Exscientia, the use of AI in drug discovery, and more.
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Chris Gibson - Co-Founder and Chief Executive Officer Najat Khan - Chief ...
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
On Thursday, Exscientia plc EXAI agreed to merge with Recursion Pharmaceuticals Inc. RXRX.
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
SALT LAKE CITY, Aug. 08, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Recursion (Nasdaq: RXRX), please note that in the first bullet under "Additional Corporat...
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
Operational complementarities expected to yield annual synergies of approximately $100 million Operational complementarities expected to yield annual synergies of approximately $100 million
Biotech firm Recursion to buy smaller peer Exscientia for $688 million
Recursion Pharmaceuticals , a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival Exscientia for $688 million in an all-stock deal, accordi...
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and...
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
Company to host public L(earnings) call on August 8th at 5:00 pm ET / 3:00 pm MT Company to host public L(earnings) call on August 8th at 5:00 pm ET / 3:00 pm MT
Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts
Recursion Pharmaceuticals uses AI in drug development, increasing success rates in lab and animal testing, with upcoming data readouts for five Phase 2 programs. The company is a "TechBio," with partn...
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discover...
Recursion Announces Proposed Offering of Class A Common Stock
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discover...